BPTH Bio-Path Total Debt to Capital

Bio-Path Holdings (BPTH) focuses on implementing antisense molecules for leukemia therapy, seeking to attract investment through clinical reports. Processes rely on bioethics and eco-friendly waste disposal. This chart of the total debt-to-equity ratio is fixed at 0.00. The business operates under intense competition with biotech leaders, where success is determined solely by high drug efficacy.

The total debt-to-equity ratio measures the proportion of borrowed funds within the financing structure, determining the business's level of dependence on creditors and the associated default risks. By analyzing the current total liabilities-to-equity level, an investor assesses the financial stability of Bio-Path Holdings (BPTH), whose investments in the DNAbilize platform for targeted cancer therapy require strict control over the debt load.